SCHEMBL6983547

SCHEMBL6983547

CC(C)(C)OC(=O)NC(Cc1ccccc1)C(=O)N1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.63
PABPC1 P11940 1/20 0.62
POLB P06746 3/20 0.61
KMT2A Q03164 4/20 0.58
P2RX7 Q99572 1/20 0.57
MAPK1 P28482 1/20 0.54
HRH2 P25021 1/20 0.53
HRH1 P35367 1/20 0.53
CTSS P25774 3/20 0.53
CTSK P43235 2/20 0.53
GAA P10253 1/20 0.52
GFER P55789 1/20 0.52
CTSL P07711 1/20 0.50
CTSB P07858 1/20 0.50
TP53 P04637 1/20 0.50
MEN1 O00255 2/20 0.49
ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5748353 0.91 PABPC1 (0.53) KDM4EPABPC1POLBKMT2AP2RX7
SCHEMBL5748365 0.91 PABPC1 (0.53) KDM4EPABPC1POLBKMT2AP2RX7
SCHEMBL9483845 0.87 KMT2A (0.56) PABPC1POLBKMT2AP2RX7MAPK1
SCHEMBL9483838 0.87 KMT2A (0.56) PABPC1POLBKMT2AP2RX7MAPK1
SCHEMBL6985876 0.87 KMT2A (0.58) PABPC1KMT2AP2RX7MAPK1HRH2
SCHEMBL7390948 0.86 PABPC1 (0.61) KDM4EPABPC1KMT2AP2RX7MAPK1
SCHEMBL7390953 0.86 PABPC1 (0.61) KDM4EPABPC1KMT2AP2RX7MAPK1
SCHEMBL4510471 0.86 MC4R (0.56) PABPC1POLBKMT2AP2RX7MAPK1
SCHEMBL27488200 0.85 POLB (0.71) KDM4EPOLBKMT2AMAPK1GFER
SCHEMBL6981597 0.85 MAPK1 (0.52) KDM4EPABPC1POLBKMT2AP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
US-5935959-A CYSTEINE PROTEASE INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 1999-08-10 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
CN-1163145-A Inhibiting agent for vascular formation SENJI SEIYAKU K K (JP) 1997-10-29 CN disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed